Vysis to defend patent licensed to Gen-Probe.
"In our view, this suit has been brought because the anticipated royalty payments to Vysis under the Collins license greatly exceed the cost of a lawsuit to try to invalidate the patent," stated John L. Bishop, Vysis president and CEO. "Although no one likes litigation, the significant technological advance of the Collins patent makes us confident of a favorable outcome."
The patented technology was invented in the mid-1980's and relates to pathogen detection methods that achieve high clinical sensitivity by coupling Vysis' reversible target capture technology with enzymatic nucleic acid amplification techniques, such as the polymerase chain reaction, Q-beta replicase, and transcription mediated amplification. The utility of the patented technology was proven by Vysis in clinical trials using an automated DNA probe testing instrument in 1994-95, as reported by Smith, et al. in the Journal of Clinical Microbiology Vol. 35, No. 6, June 1997 at 1477-83 and 1484-91, where use of the patented technology greatly improved the clinical sensitivity of the assay.
Chiron has announced that the clinical trials of the Gen-Probe nucleic acid testing product currently encompass testing of approximately 70 percent of the United States blood supply, and financial analysts expect its FDA approval in mid-2000. "We are confident that our patent rights will be sustained and that Gen-Probe's HIV/HCV product will be found to infringe those rights," stated Norval B. Galloway, Vysis patent counsel.
In November 1999, Vysis announced goals of achieving break-even status of its operations in the fourth quarter of 2000, and profitability for the full year 2001. "We have evaluated these goals in light of the litigation expense we estimate for this suit and we have decided not to adjust these goals. Vysis has recently significantly reduced its operating expenses in Europe by the appointments of exclusive distributors in France and Italy, and we believe these reductions mitigate the financial impact from the expected cost of the suit," stated Bishop.
Vysis is a genomic disease management company that develops, commercializes and markets clinical products providing information critical to the evaluation and management of cancer, prenatal disorders and other genetic diseases. The company has direct sales operations in the United States and Europe, a marketing partnership in Japan with Fujisawa Pharmaceutical Co. (Osaka, Japan; 06-202-1141), and a worldwide distribution network.
|Printer friendly Cite/link Email Feedback|
|Comment:||Vysis to defend patent licensed to Gen-Probe.|
|Publication:||BIOTECH Patent News|
|Article Type:||Brief Article|
|Date:||Jan 1, 2000|
|Previous Article:||Ventana sues Cytologix for patent infringement.|
|Next Article:||Federal Appeals Court affirms Pioneer's right to patent seeds and plants.|
|Enzo Biochem files suit against eight Life Science companies. (Executive Briefing).|
|Gen-Probe granted summary judgment in Enzo patent lawsuit.|
|Appeals court affirms summary judgment in favor of Gen-Probe in Enzo patent lawsuit.|